{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:11:21Z","timestamp":1762603881062},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T00:00:00Z","timestamp":1393200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:p>A previous interim report of MM\u2010011, the first study that combined lenalidomide with anthracycline\u2010based chemotherapy followed by lenalidomide maintenance for relapsed and\/or refractory multiple myeloma (RRMM), showed promising safety and activity. We report the long\u2010term outcomes of all 76 treated patients with follow\u2010up \u22655 years. This single\u2010center phase I\/II study administered lenalidomide (10 mg on days 1\u201321 of every 28\u2010day cycle), intravenous liposomal doxorubicin (40 mg\/m<jats:sup>2<\/jats:sup> on day 1), dexamethasone (40 mg on days 1\u20134), and intravenous vincristine (2 mg on day 1). After 4\u20136 planned induction cycles, lenalidomide maintenance therapy was given at the last tolerated dose until progression, with or without 50 mg prednisone every other day. The median number of previous therapies was 3 (range, 1\u20137); 49 (64.5%) patients had refractory disease. Forty\u2010three (56.6%) patients received maintenance therapy. Grade 3\/4 adverse events occurred during induction and maintenance therapy in 48.7% and 25.6% of patients, respectively. Four (5.3%) treatment\u2010related deaths occurred during induction. Responses were seen in 53.0% (at least partial response) and 71.2% (at least minor response) of patients. Overall, median progression\u2010free survival and overall survival were 10.5 and 19.0 months, respectively; in patients with refractory disease these values were 7.5 and 11.3 months, respectively. Lenalidomide with anthracycline\u2010based chemotherapy followed by maintenance lenalidomide provided durable control in patients with RRMM (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> number, NCT00091624). Am. J. Hematol. 89:349\u2013354, 2014. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23639","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T10:26:24Z","timestamp":1385375184000},"page":"349-354","source":"Crossref","is-referenced-by-count":9,"title":["Mature results of MM\u2010011: A phase I\/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed\/refractory multiple myeloma"],"prefix":"10.1002","volume":"89","author":[{"given":"Aleksandr","family":"Lazaryan","sequence":"first","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad A.","family":"Hussein","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic J.","family":"Reu","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Faiman","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky","family":"Habecker","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Ann Karam","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Reed","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Waksman","sequence":"additional","affiliation":[{"name":"Brightech International Somerset New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie","family":"Bruening","sequence":"additional","affiliation":[{"name":"Quantitative Health Sciences, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordan","family":"Srkalovic","sequence":"additional","affiliation":[{"name":"Medical Oncology\/Hematology Sparrow Cancer Center Lansing Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Andresen","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Kalaycio","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Sweetenham","sequence":"additional","affiliation":[{"name":"UC San Diego Nevada Cancer Institute Las Vegas Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dean","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Knight","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome B.","family":"Zeldis","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,2,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.1.380"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00250-4"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-suppl_3-39"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.889"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl313"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404428"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405016"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0967-4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184135"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.51"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334755"},{"key":"e_1_2_6_21_1","unstructured":"Multiple Myeloma.Taussig Cancer Center outcomes2011.26. Available at:http:\/\/my.clevelandclinic.org\/Documents\/outcomes\/2011\/outcomes\u2010cancer\u20102011.pdf."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood.V120.21.449.449","article-title":"The novel KSP inhibitor ARRY\u2010520 is active both with and without low\u2010dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study","volume":"120","author":"Shah J","year":"2012","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23639","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:33:30Z","timestamp":1696606410000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,24]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/ajh.23639"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23639","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,24]]}}}